1-azasugar inhibitors: evidence for the 'direct
binding' model. Biochem. J., 349(pt. 1), 211-215
(2000).
4. Saul, R., et al., Castanospermine, a
tetrahydroxylated alkaloid that inhibits beta-
glucosidase
Microbiology and Immunology, 108, 115-127
(1984).
4. Jones, P.A. at al., Inhibition of DNA methylation by
5-azacytidine. Recent Results in Cancer
Research, 84, 202-211 (1983).
5. Constantinides
Growth
factors and their Receptors. Sporn, M., Roberts, A.,
eds., Berlin, Springer-Verlang. pp. 211-248 (1990).
6. Smith, J., et al., Expression of a Xenopus homolog
of Brachyury (T) is an immediate-early
chymotrypsin activity which may be present.
References
1. Cunningham, L.W., Jr., J. Biol. Chem., 211(1),
13-19 (1954).
2. Walsh, K.A., Meth. Enzymol., 19, 41-63 (1970).
3. Keil, B., in The
Cyclodextrin Technology, Szejtli, J., Kluwer
Academic Publishers (Dordrecht-Boston-London:
1988), pp. 211-215.
9. Rekharsky, M. K., et al., Complexation
thermodynamics of cyclodextrins. Chem. Rev. 98
fibroblast cell line
measured by a combination of fluorescent dyes.
Methods Mol.Biol. 1995; 43:211-8: 211-218.
78. Maines JZ, Sunnarborg A, Rogers LM,
Mandavilli A, Spielmann R, Boyd FT: Positive
126(1),
37-45 (2011).
4. Treeck, O. et al., Polymorphisms in the promoter
region of ESR2 gene and breast cancer
susceptibility. J. Steroid Biochem. Mol. Biol.,
114(3-5), 207-211 (2009).
5. Maquire
example, 108
Jurkat cells grown in RPMI plus 10% FBS can
be extracted in 1 mL of Extraction Buffer.
5. Transfer extracts to microcentrifuge tubes and
centrifuge at 13,000 rpm for 10 minutes at 4 ºC.
receptor provides an
essential survival signal for SOS-dependent skin
tumor development. Cell, 102, 211-220 (2000).
8. Keilhack, H., et al. Phosphotyrosine 1173 mediates
binding of the protein-tyrosine
receptor provides an
essential survival signal for SOS-dependent
skin tumor evelopment. Cell, 102, 211-220
(2000).
8. Keilhack, H., et al., Phosphotyrosine 1173
mediates binding of the protein-tyrosine
van Reis R, Zydney A. Membrane
Separations in Biotechnology. Curr. Op.
Biotechnol. 12(2) 2001: 208–211. doi: 10.1016/
S0958-1669(00)00201-9.
11 Besnard L, et al. Clarification of
Vaccines: An Overview